ArticleBritish journal of haematology2020
Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
Article in British journal of haematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.Blood neoplasia · 2025Trial
- Trial
- Clinical applications of mass spectrometry in multiple myeloma.Blood advances · 2025Review
- Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients.Scientific reports · 2024Article
- Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- [Minimal residual disease assessment and progress in multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Review
- Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma.Oncology research · 2023Article
- Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy.Transplantation and cellular therapy · 2022Article
- Article
- Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse.Frontiers in oncology · 2022Article
- Review
- The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.Transplantation and cellular therapy · 2021Review
- Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology-Highlights of the 8th Heidelberg Myeloma Workshop.Cancers · 2021Article
- Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.Clinica chimica acta; international journal of clinical chemistry · 2021Article
- MRD Assessment in Multiple Myeloma: Progress and Challenges.Current hematologic malignancy reports · 2021Review
- Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.Blood reviews · 2021Review
- Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.Blood cancer journal · 2021Article
- International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.Leukemia · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF MS) may soon replace routine electrophoretic methods for monitoring monoclonal proteins in patients with multiple myeloma. To further evaluate the clinical utility of this assay, we compared the performance of MALDI-TOF-MS head-to-head with an established bone marrow-based measurable residual disease assay by flow cytometry (Flow-BM-MRD), using Memorial Sloan Kettering Cancer Center's 10-color, single-tube method. Our results suggest that MALDI-TOF-MS adds value to bone marrow-based MRD testing and may be most useful for early detection of relapse in peripheral blood compared to current electrophoretic methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.